Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

NCT04992949 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myeloproliferative Syndrome

Interventions

DRUG: CPX-351

Sponsor

French Innovative Leukemia Organisation

Collaborators

[object Object]
[object Object]